PAR
Paradigm Biopharmaceuticals Limited
1 day chart
About PAR
Paradigm Biopharmaceuticals Limited (PAR) is involved in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs, thereby reducing the cost and time to bring therapeutics to market.
Buy Australian shares starting with PAR. Invest today with a CHESS-sponsored investing platform!
Market Capitalisation
$191M
Price-earnings ratio
-3.96
Dividend yield
NaN%
High today
$0.77
Low today
$0.68
Open price
$0.73
52-week high
$2.00
52-week low
$0.61
Announcements
PAR FAQs
Can I buy PAR shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake platform allows you to buy PAR shares and over 8,000 stocks and ETFs across the ASX and Wall St.
How much is one share of Paradigm Biopharmaceuticals Limited?
One share of Paradigm Biopharmaceuticals Limited is valued at $0.68.
What is the ticker symbol for Paradigm Biopharmaceuticals Limited?
The ticker symbol for Paradigm Biopharmaceuticals Limited is PAR.
How do I buy PAR shares in Australia?
To buy PAR stocks in Australia you'll need to open an account with an investing platform like Stake.
To do so follow these steps:
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake AUS
- Deposit directly into your Stake wallet and you're ready to invest in PAR
What is the 52-week high for Paradigm Biopharmaceuticals Limited stock?
The Paradigm Biopharmaceuticals Limited 52-week high stock price is $2.00.
What is the 52-week low for Paradigm Biopharmaceuticals Limited stock?
The Paradigm Biopharmaceuticals Limited 52-week low stock price is $0.61.
What is the market capitalisation of Paradigm Biopharmaceuticals Limited PAR?
As of 16/09/2023 Paradigm Biopharmaceuticals Limited has a market cap of $191M.
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.